First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

被引：0

作者：

Camidge, D. Ross

Bazhenova, Lyudmila

Salgia, Ravi

Weiss, Glen J.

Langer, Corey J.

Shaw, Alice Tsang

Narasimhan, Narayana I.

Dorer, David J.

Rivera, Victor M.

Zhang, Joshua

Clackson, Tim

Haluska, Frank G.

Gettinger, Scott N.

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] UC San Diego Moores Canc Ctr, La Jolla, CA USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Virginia G Piper Canc Ctr, Scottsdale Healthcare Program, Scottsdale, AZ USA

[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[7] ARIAD Pharmaceut Inc, Cambridge, MA USA

[8] Yale Univ, Sch Med, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8031

引用

页数：1

共 50 条

[41] First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
Postel-Vinay, S.
Herbschleb, K.
Massard, C.
Woodcock, V.
Ocker, M.
Wilkinson, G.
Walter, A.
Ewerton, F.
Poelman, M.
Middleton, M.
Soria, J. C.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S7 - S8
[42] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
Yu, Xianjun
Zhang, Jian
Sun, Yuping
Deng, Yanhong
Guo, Shuangshuang
Hong, Wei
Shi, Si
Liu, Rujiao
Gao, Shuiping
Dang, Qi
Zhang, Jianwei
Su, Weiguo
Shi, Michael
Fan, Songhua
Zhang, Bo
Pan, Beiqing
Jia, Xiaoyun
Wang, Jian
Zhong, Chen
Ma, Luguang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).
von Tresckow, Bastian
Gundermann, Stefan
Eichenauer, Dennis A.
Aulitzky, Walter Erich
Goebeler, Mariele
Sayehli, Cyrus
Bacchus, Liza
Hauns, Bernhard
Mais, Anna
Hentsch, Bernd
Kohihof, Hella
Krauss, Rolf
Krauss, Babett
Baumgartner, Roland
Vitt, Daniel
Engert, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Juric, Dejan
de Bono, Johann S.
LoRusso, Patricia M.
Nemunaitis, John
Heath, Elisabeth I.
Kwak, Eunice L.
Macarulla Mercade, Teresa
Geuna, Elena
de Miguel-Luken, Maria Jose
Patel, Chirag
Kuida, Keisuke
Sankoh, Serap
Westin, Eric H.
Zohren, Fabian
Shou, Yaping
Tabernero, Josep
CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023
[45] First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Subbiah, Vivek
Khawaja, Muhammad Rizwan
Hong, David S.
Amini, Behrang
Jiang Yungfang
Hui Liu
Johnson, Adrienne
Schrock, Alexa B.
Ali, Siraj M.
Sun, James X.
Fabrizio, David
Piha-Paul, Sarina
Fu, Siqing
Tsimberidou, Apostolia M.
Naing, Aung
Janku, Filip
Karp, Daniel D.
Overman, Michael
Eng, Cathy
Kopetz, Scott
Meric-Bernstam, Funda
Falchook, Gerald S.
JCI INSIGHT, 2017, 2 (08):
[46] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
DiNardo, Courtney D.
Montesinos, Pau
Benajiba, Lina
Triguero, Ana
Recher, Christian
Schuh, Andre C.
Heiblig, Mael
Bajel, Ashish
Pigneux, Arnaud
Alonso-Domiguez, Juan M.
Fathi, Amir T.
Grove, Carolyn
Hou, Hsin-An
Heuser, Michael
Assouline, Sarit
Fleming, Shaun
Shin, Dong-Yeop
Sweet, Kendra
Odenike, Olatoyosi
Altman, Jessica
Ooi, Melissa Gaik Ming
Lao Zhentang
Vey, Nobert
Zeidner, Joshua
Salhotra, Amandeep
Wang, Eunice
Schiller, Gary
Porkka, Kimmo
Zuckerman, Tsila
Havelange, Violaine
Jonas, Brian A.
Narayanan, Sujaatha
Jang, Jun Ho
Lee, Je-Hwan
Szpurka, Anna M.
Heirich, Dana
Chen, Hsiao Rong
Hanft, Violet
Zhao, Junjie
Gueorguieva, Ivelina
Zhang, Yin
Stein, Eytan M.
CANCER RESEARCH, 2023, 83 (08)
[47] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elena Elez
Carlos Gomez-Roca
Arturo Soto Matos-Pita
Guillem Argiles
Thibaud Valentin
Cinthya Coronado
Jorge Iglesias
Teresa Macarulla
Sarah Betrian
Salvador Fudio
Katrin Zaragoza
Josep Tabernero
Jean-Pierre Delord
Investigational New Drugs, 2019, 37 : 674 - 683
[48] First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
He, Aiwu Ruth
Cohen, Roger B.
Denlinger, Crystal S.
Sama, Ashwin
Birnbaum, Ariel
Hwang, Jimmy
Sato, Takami
Lewis, Nancy
Mynderse, Michelle
Niland, Michele
Giles, Jennifer
Wallin, Johan
Moser, Brian
Zhang, Wei
Walgren, Richard
Plimack, Elizabeth R.
ONCOLOGIST, 2019, 24 (09): : E930 - E942
[49] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elez, Elena
Gomez-Roca, Carlos
Soto Matos-Pita, Arturo
Argiles, Guillem
Valentin, Thibaud
Coronado, Cinthya
Iglesias, Jorge
Macarulla, Teresa
Betrian, Sarah
Fudio, Salvador
Zaragoza, Katrin
Tabernero, Josep
Delord, Jean-Pierre
INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
[50] Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
Cook, Natalie
Blagden, Sarah
Lopez, Juanita
Sarker, Debashis
Greystoke, Alastair
Haris, Noor Md
Kazmi, Farasat
Anam, Kaiser
Franco, Ana Ortego
Pihlak, Rille
Goodwin, Louise
Wilson, David
Phillips, Caroline
Robertson, Jane
Timmis, Helen
Tilston, Craig
Woodcock, Simon A.
Plummer, Ruth
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →